ABSTRACT
Positive airway pressure (PAP) therapy has been the standard treatment of choice for sleep disordered breathing, with 29–83% of patients being noncompliant. With the advent of newly Food and Drug Adminisatration (FDA)-approved implantable stimulators for treating sleep disordered breathing in a fraction of noncompliant PAP therapy patients, the landscape of sleep medicine and sleep technology is changing to narrow the gap between compliant and non-compliant patients. The remedē® System for treating central sleep apnea and the Inspire® upper airway stimulation (UAS) therapy for treating obstructive sleep apnea are providing new tools for sleep physicians, elevating sleep technologists’ expertise, and paving the way for personalized medicine.
DISCLOSURE STATEMENT
EMV consulted for ReVENT Medical, Inc., and Nyxoah S.A.